SEC Filings
LSV Holds 5.48% Of GoodRx Class A Shares Without Seeking To Influence Control
The investment adviser's position accompanies GoodRx's push to put prescription savings information inside Google Cloud's healthcare tools.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The investment adviser's position accompanies GoodRx's push to put prescription savings information inside Google Cloud's healthcare tools.
SEC Filings
The adviser reported voting authority over 4.3 million shares and certified that its holding was not aimed at changing control.
Earnings
Management expects to reach its debt goal in 2027, while tying dividend growth to cash generation at $50.00 oil.
SEC Filings
The adviser controls sales of the reported shares but has no voting authority, and no individual client owns more than 5%.
SEC Filings
The previous $1.5 billion repurchase program had $216 million left at September 30; the board also declared $0.53 a share.
SEC Filings
The passive holding sits against a canceled $39.00-per-share takeover offer and higher third-quarter revenue.
Earnings
The changes took effect Tuesday, and the board also declared a quarterly cash dividend of $1.09 per share.
Earnings
Management defended the nutrition expansion as analysts questioned complexity, investment needs and the timing of the deal.
SEC Filings
Disclosed holdings rose to $63.7 billion from $59.9 billion, while the number of positions fell to 420 from 424.
Markets
A non-cash loan valuation loss added to the quarterly net loss, while shares entered Tuesday down 41% for the year.
Markets
Most early ISEMBYLD enrollees are expected to start infusions in 2027, management said, after the first patients began in October.
Markets
The ownership update reflected no new trading, while Fate reported early lupus responses without preparatory chemotherapy.